These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 31322176)

  • 21. [Study on histone deacetylase inhibitor LBH589 induces apoptosis of multiple myeloma cells and its reversal of drug resistance mechanism].
    Zhang L; Ma YP; Jia G
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):926-31. PubMed ID: 23363750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.
    Chauhan D; Li G; Hideshima T; Podar K; Mitsiades C; Mitsiades N; Catley L; Tai YT; Hayashi T; Shringarpure R; Burger R; Munshi N; Ohtake Y; Saxena S; Anderson KC
    Blood; 2003 Nov; 102(9):3379-86. PubMed ID: 12855565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Multiple myeloma cell line U266 apoptosis induced by velcade].
    Chen LJ; Li JY; Qian SX; Zhu GR; Zheng WJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Aug; 14(4):696-9. PubMed ID: 16928302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Icaritin Reverses Multidrug Resistance of Multiple Myeloma Cell Line KM3/BTZ].
    Li ZY; Li ZJ; Chen X; Huang XR; Fang ZQ; Zhang JG; Fang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1690-1695. PubMed ID: 29262899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13.
    Zhang G; Miao F; Xu J; Wang R
    Bosn J Basic Med Sci; 2020 May; 20(2):209-217. PubMed ID: 31538911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ectopic cyclin D1 overexpression increases chemosensitivity but not cell proliferation in multiple myeloma.
    Kuroda Y; Sakai A; Tsuyama N; Katayama Y; Munemasa S; Asaoku H; Okikawa Y; Nakaju N; Mizuno M; Ogawa K; Nishisaka T; Matsui H; Tanaka H; Kimura A
    Int J Oncol; 2008 Dec; 33(6):1201-13. PubMed ID: 19020753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A cohort study comparing the efficacy and safety of bortezomib plus dexamethasone versus bortezomib, epirubicin and dexamethasone in patients with multiple myeloma].
    Hao QY; Chen H; Liu KY; Wen L; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2016 Sep; 55(9):689-94. PubMed ID: 27586976
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-Methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating Heat Shock Protein-27.
    Chauhan D; Li G; Auclair D; Hideshima T; Podar K; Mitsiades N; Mitsiades C; Chen LB; Munshi N; Saxena S; Anderson KC
    Apoptosis; 2004 Mar; 9(2):149-55. PubMed ID: 15004512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of stable multiple myeloma cell line with overexpressed PDCD5 and its proapoptosis mechanism.
    Feng W; Fu Y; Zhang Y; Lv B; Li X; Zhang F; Gui R; Liu J
    Int J Clin Exp Pathol; 2015; 8(9):10635-43. PubMed ID: 26617773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.
    Ramakrishnan V; Mager DE
    J Pharmacol Exp Ther; 2018 Jun; 365(3):734-751. PubMed ID: 29632237
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
    Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synergistic apoptotic effect of arabinoxylan rice bran (MGN-3/Biobran) and curcumin (turmeric) on human multiple myeloma cell line U266 in vitro.
    Ghoneum M; Gollapudi S
    Neoplasma; 2011; 58(2):118-23. PubMed ID: 21275460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.
    Łuczkowska K; Kulig P; Rusińska K; Baumert B; Machaliński B
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Establishment of BOR-Resistant U266 Cell Line and the Detection of Its Biological Activities].
    Liu HL; Que WZ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1722-1726. PubMed ID: 29262905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ANXA7 promotes the cell cycle, proliferation and cell adhesion-mediated drug resistance of multiple myeloma cells by up-regulating CDC5L.
    Liu H; Guo D; Sha Y; Zhang C; Jiang Y; Hong L; Zhang J; Jiang Y; Lu L; Huang H
    Aging (Albany NY); 2020 Jun; 12(11):11100-11115. PubMed ID: 32526706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bortezomib could down-regulate the expression of RANKL, inhibit cell proliferation and induce cell apoptosis in the human myeloma cell line RPMI 8226 by activating casepase-3.
    Lin L; Chen D; Xiang ZF; Pei RZ; Zhang PS; Liu XH; Du XH; Lu Y
    Cancer Biomark; 2017 Aug; 20(2):217-224. PubMed ID: 28869453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
    Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
    Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [IL-6 Regulates the Chemosensitivity of Drug-Resistant Multiple Myeloma Cell Lines to Bortezomib through STAT3/Notch Signaling Pathway].
    Liu Y; Sui JZ; Zhu LH; Dai Y; Dong HQ; Cheng P
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1474-1481. PubMed ID: 36208252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma.
    Wang Q; Shi Q; Chen Y; Wang G; Shen L
    Leuk Res; 2023 Apr; 127():107041. PubMed ID: 36801701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.